Video

Dr. Brugarolas on rationale for targeting HIF2α in renal cell carcinoma

Author(s):

Urology Times staff

“One of the processes that is regulated by HIF2α is angiogenesis,” says James Brugarolas, MD, PhD.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected

      James Brugarolas, MD, PhD, director of the Kidney Cancer Program at Harold C. Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, discusses the rationale for developing therapies for renal cell carcinoma that target HIF2α.

      Related Videos
      Study data point to gender disparities in oncology research citations
      Study data point to gender disparities in oncology research citations
      Nitin Yerram, MD, highlights new resource center for patients with renal cell carcinoma
      Nitin Yerram, MD, highlights new resource center for patients with renal cell carcinoma
      Betty Wang, MD, discusses studies from the 2025 EAU meeting
      Betty Wang, MD, recaps 3 key urologic cancer studies from EAU 2025
      Darren Feldman, MD, on study of 177Lu-girentuximab plus nivolumab for ccRCC
      Darren Feldman, MD, on study of 177Lu-girentuximab plus nivolumab for ccRCC
      Francesca Jackson-Spence, MBChB, details the ongoing SAMETA trial in papillary renal cancer
      Francesca Jackson-Spence, MBChB, details the ongoing SAMETA trial in papillary renal cancer
      Kate Gessner, MD, on systemic agents vs MDT after kidney cancer progression
      Kate Gessner, MD, on systemic agents vs MDT after kidney cancer progression
      Taylor Goodstein, MD, highlights project on staging in larger kidney tumors
      Taylor Goodstein, MD, highlights project on staging in larger kidney tumors
      Chad Tang, MD: Considerations for SBRT in metastatic RCC
      Chad Tang, MD: Considerations for SBRT in metastatic RCC
      Considering patient-reported outcomes in kidney cancer care, with Nicholas Zaorsky, MD, PhD
      Considering patient-reported outcomes in kidney cancer care, with Nicholas Zaorsky, MD, PhD
      Nicholas Zaorsky, MD, MS: Protecting kidney function after local renal cell carcinoma therapy
      Nicholas Zaorsky, MD, MS: Protecting kidney function after local renal cell carcinoma therapy
      Related Content
      Perioperative lenvatinib/pembrolizumab shows promise in non-metastatic ccRCC
      April 3rd 2025

      Perioperative lenvatinib/pembrolizumab shows promise in non-metastatic ccRCC

      Mehmet Asim Bilen, MD Hannah Clarke
      "The combination demonstrated clinical activity and an acceptable safety profile in the perioperative setting for locally advanced, non-metastatic clear cell RCC," says Mehmet Asim Bilen, MD.
      Close-up shot of microscope with metal lens at laboratory. | Image Credit: © kkolosov - stock.adobe.com
      April 2nd 2025

      The importance of federal funding in cancer research: A call to action

      Michael S. Cookson, MD, MMHC
      "We must lobby to maintain our current funding levels and push for increased support to continue driving progress in cancer care," says Michael S. Cookson, MD, MMHC, FACS.
      FDA updates in urology: March 2025
      April 1st 2025

      FDA updates in urology: March 2025

      Hannah Clarke
      A recap of the FDA submissions and regulatory decisions in urology from March 2025.
      Subcutaneous nivolumab under review in EU for solid tumors
      March 31st 2025

      Subcutaneous nivolumab under review in EU for solid tumors

      Hannah Clarke
      The European Commission must issue a decision on the application on or by June 2, 2025.
      Sintilimab/fruquintinib combo meets primary PFS end point in advanced RCC
      March 19th 2025

      Sintilimab/fruquintinib combo meets primary PFS end point in advanced RCC

      Hannah Clarke
      "The positive results from this phase 3 study of the sintilimab and fruquintinib combination represent a significant advancement in the treatment of advanced renal cell carcinoma,” says Prof Zhisong He.
      FDA greenlights trial of orellanine in metastatic renal cell carcinoma
      March 18th 2025

      FDA greenlights trial of orellanine in metastatic renal cell carcinoma

      Hannah Clarke
      The study will evaluate the investigational drug product ONC175 (orellanine) in patients with metastatic clear cell or papillary renal cell carcinoma.
      © 2025 MJH Life Sciences

      All rights reserved.